http://rdf.ncbi.nlm.nih.gov/pubchem/patent/PH-12020500228-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4cdb1ef9fe36ae01e3729156a7103103
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2086
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-209
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
filingDate 2020-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0cfd53cb49013dbf9f08795b95658ce2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f40941594515ad418eb81842fe783e1d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_627483b9b90680eb09398530de193eed
publicationDate 2020-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber PH-12020500228-A1
titleOfInvention Pharmacutical composition comprising remogliflozin and antidiabetic agent
abstract The invention relates to a pharmaceutical composition comprising remogliflozin or pharmaceutically acceptable salt or ester thereof, and metformin or pharmaceutically acceptable salt thereof. In particular, it relates to an immediate release pharmaceutical composition comprising: (a) remogliflozin or pharmaceutically acceptable salt or ester thereof, (b) metformin or pharmaceutically acceptable salt thereof, and (c) a pharmaceutically acceptable excipient.
priorityDate 2018-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419497074
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID422225960
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4091
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9846588

Total number of triples: 29.